PTYLTD
    • Free Reports
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic
  • Insights From Technical Analysis

Insights From Technical Analysis

Avecho Biotechnology (ASX: AVE)

Avecho Biotechnology (ASX: AVE): Breakout Above Long-Term Resistance Puts Trend Sustainability in Focus

Jun 26, 2026
Proactive Equities Team

Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.

4DMedical (ASX: 4DX)

4DMedical (ASX: 4DX) Pulls Back After Breakout Rally

Jun 26, 2026
Proactive Equities Team

4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.

Auckland International Airport (ASX: AIA)

Auckland International Airport (ASX: AIA): Infrastructure Momentum Meets Earnings Resilience

Jun 24, 2026
Proactive Equities Team

Auckland Airport (ASX: AIA) delivers steady earnings growth, strong passenger recovery, and disciplined infrastructure execution, positioning New Zealand’s gateway for long‑term value creation.

WiseTech Global (ASX: WTC)

WiseTech Global Drops Sharply as Investors Rush for the Exit

Jun 24, 2026
Proactive Equities Team

WiseTech Global shares have fallen sharply amid bearish sentiment and heavy selling pressure. The logistics software company continues to expand its CargoWise platform and invest in AI and digital trade solutions, but investors remain cautious as the stock trades near multi-month lows.

Clinuvel Pharmaceuticals (ASX: CUV)

Is Breakout in Clinuvel Pharmaceuticals (ASX: CUV) Signalling a Sustainable Bullish Reversal?

Jun 24, 2026
Proactive Equities Team

CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.

Lotus Resources (ASX: LOT)

Lotus Resources (ASX: LOT) Surges as Selling Pressure Continues to Ease

Jun 23, 2026
Proactive Equities Team

Lotus Resources (ASX: LOT) jumped 14% to $0.66 as investors responded to improving uranium market sentiment and progress at its Kayelekera and Letlhakane projects. The company continues to ramp up production in Malawi while advancing plans to become a potential 5.5 M lb-per-year uranium producer.

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

12345...25
Page 2 of 25